Recent Posts

jCyte Presents Results of Clinical Testing in Retinitis Pigmentosa December 14, 2017 - December 14, 2017 - Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa (RP). Presented by David S. Boyer, MD, at the annual Read More >
Where Our Retinitis Pigmentosa Therapy is Right Now July 17, 2017 - In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute for Regenerative Medicine (CIRM). In April, we announced our phase Read More >
jCyte Receives Regenerative Medicine Advanced Therapy Designation May 2, 2017 - May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the company’s developmental retinitis pigmentosa (RP) treatment, jCell. RMAT seeks Read More >